HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned

— ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — 

— Robust PFS gains alongside very encouraging OS clinical benefit in this treatment-naïve biomarker-selected patient population — 

— Offers a potential new standard of care through an all-oral, biomarker-driven frontline strategy for MET-overexpressing, EGFR-mutated lung cancer patients —